Retrospective Study of Chemotherapy-Induced Peripheral Neuropathy in Gastrointestinal Cancer Patients Receiving Oxaliplatin

Retrospective Study of Chemotherapy-Induced Peripheral Neuropathy in Gastrointestinal Cancer Patients Receiving Oxaliplatin - Retrospective Study of Chemotherapy-Induced Peripheral Neuropathy in Gastrointestinal Cancer Patients Receiving Oxaliplatin

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000052950

Enrollment

200

Registered

2023-12-01

Start date

2023-12-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Colon cancer, gastric cancer, esophageal cancer, pancreatic cancer, biliary tract cancer, small intestine cancer, appendix cancer

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1.Patients diagnosed with gastrointestinal cancer. 2.Chemotherapy including oxaliplatin was started at the Department of Oncology, St. Marianna University Hospital from January 1, 2020 to September 30, 2023.

Exclusion criteria

Exclusion criteria: Cases in which the principal investigator determines that participation in this study is inappropriate

Design outcomes

Primary

Measure	Time frame
Percentage of chemotherapy-induced peripheral neuropathy of Grade 2 or higher with or without proton pump inhibitor or H2-receptor antagonist use	—

Secondary

Measure	Time frame
Time to onset of grade 2 or higher chemotherapy-induced peripheral neuropathy with and without use of proton pump inhibitors and H2-receptor antagonists, and percentage of chemotherapy intolerance due to chemotherapy-induced peripheral neuropathy	—

Countries

Japan

Contacts

Public ContactYoshiyasu Uchida

St. Marianna Medical University Division of clinical oncology

yoshiyasu.uchida@marianna-u.ac.jp044-977-8111

Outcome results